Literature DB >> 29658339

Refractory hypercalcaemia secondary to localised gastrointestinal stromal tumour.

T Hart1, D Sinitsky2, A Shamsiddinova3, A Rohatgi2.   

Abstract

Gastrointestinal stromal tumours are a rare form of intra-abdominal neoplasm derived from mesenchymal tissue, typically presenting with abdominal pain, anaemia or bleeding into the bowel or abdominal cavity. Hypercalcaemia is an unusual complication, having been documented in only seven previous patients, all of whom had advanced metastatic disease. We present a case of treatment-resistant hypercalcaemia in a patient with non-metastatic gastrointestinal stromal tumour, which resolved following excision of the tumour.

Entities:  

Keywords:  Gastrointestinal stromal tumour hypercalcaemia; Gastrointestinal stromal tumours

Mesh:

Year:  2018        PMID: 29658339      PMCID: PMC6111900          DOI: 10.1308/rcsann.2018.0064

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  17 in total

Review 1.  Clinical practice. Hypercalcemia associated with cancer.

Authors:  Andrew F Stewart
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

2.  Metastatic gastrointestinal stromal tumour presenting as hypercalcaemia--a rare occurrence.

Authors:  A George
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-03-14       Impact factor: 4.126

3.  Metastatic gastrointestinal stromal tumor and hypercalcemia in a patient with ulcerative colitis.

Authors:  Mansour S Al-Moundhri; Khaled Al-Thahli; Said Al-Kindy; Jamal Salam; Lakshmi Rao
Journal:  Saudi Med J       Date:  2006-10       Impact factor: 1.484

Review 4.  Gastrointestinal stromal tumours: origin and molecular oncology.

Authors:  Christopher L Corless; Christine M Barnett; Michael C Heinrich
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

5.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

6.  Increased expression of 25-hydroxyvitamin D-1alpha-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy.

Authors:  Katie N Evans; Harris Taylor; Daniel Zehnder; Mark D Kilby; Judith N Bulmer; Farah Shah; John S Adams; Martin Hewison
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

7.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

8.  PDGFRA activating mutations in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

Review 9.  Role of calcium, vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis.

Authors:  Julia Höbaus; Ursula Thiem; Doris M Hummel; Enikö Kallay
Journal:  Anticancer Agents Med Chem       Date:  2013-01       Impact factor: 2.505

Review 10.  Hypercalcemia in metastatic GIST caused by systemic elevated calcitriol: a case report and review of the literature.

Authors:  Katrine Hygum; Christian Nielsen Wulff; Torben Harsløf; Anders Kindberg Boysen; Philip Blach Rossen; Bente Lomholt Langdahl; Akmal Ahmed Safwat
Journal:  BMC Cancer       Date:  2015-10-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.